Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946008 | 1.00 | RAB9A (0.53) | RAB9AFKBP1AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL7948659 | 1.00 | RAB9A (0.53) | RAB9AFKBP1AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL3172600 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL7406144 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL3172593 | 0.84 | RAB9A (0.71) | RAB9AALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL19825651 | 0.84 | RAB9A (0.54) | RAB9AFKBP1AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL10595315 | 0.83 | RAB9A (0.47) | RAB9AFKBP1AALDH1A1LMNAPREP | |
| SCHEMBL10595318 | 0.83 | RAB9A (0.47) | RAB9AFKBP1AALDH1A1LMNAPREP | |
| SCHEMBL7771061 | 0.83 | RAB9A (0.53) | RAB9AFKBP1AALDH1A1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL27968384 | 0.83 | RAB9A (0.69) | RAB9AALDH1A1L3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| CN-1033274-A | The preparation method of new Pyridazinyl amine derivative | JANSSEN PHARMACEUTICA NV (BE) | 1989-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RAB9A 2845/4885FKBP1A 760/4885ALDH1A1 1930/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RAB9A 2845/4885FKBP1A 760/4885ALDH1A1 1930/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RAB9A 2845/4885FKBP1A 760/4885ALDH1A1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.